Aura Biosciences
Aura Biosciences is a biopharmaceutical company aiming to transform the treatment of early-stage tumours to prevent metastasis and improve outcomes for patients with cancer.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells, while leaving surrounding tissue unharmed. The drugs utilize a novel technology based on the tumour targeting selectivity of virus-like particles (VLPs). The company’s lead program AU-011 is being developed for first-line treatment of choroidal melanoma, a rare and life-threatening ocular cancer.
